In June, we added 77 citations in DIDB, including 22 in vitro (with 15 articles published in June 2023) and 55 in vivo articles (with 45 articles published in June 2023).
3 recently approved NDAs/BLAs were also added: leniolisib (JOENJA), pegunigalsidase alfa (ELFABRIO), fezolinetant (VEOZAH).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
“We are thrilled to share an important development related to Drug Interaction Solutions (DIS) and the DIDB® – The Drug Interaction Database, which you and your teams have relied on over the years. As of June 21, 2023, DIS and DIDB® have been acquired by Certara – a global leader in biosimulation and technology-enabled services that accelerate drug development.
This move represents a significant milestone in the growth and development of DIDB® and further strengthens its position as an internationally recognized authoritative, unbiased, and transparent drug development tool. As a part of Certara’s data sciences portfolio, we know we have found the right home for DIDB® to continue towards becoming a standard in supporting drug development, healthcare applications, and complex clinical decision algorithms.”
UW CoMotion
In May, we added 107 citations in DIDB, including 45 in vitro (with 14 articles published in May 2023) and 62 in vivo articles (with 39 articles published in May 2023).
2 recently approved NDAs/BLAs were also added: retifanlimab (DAYBUE), tofersen (QALSODY).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
Dr. Jingjing Yu will be contributing to the Second Nordic Conference on Personalized Medicine (June 14-16, 2023 – Turku, Finland) with a presentation entitled “Drug-Drug Interactions in the New FDA Therapy Approvals: Mechanism and Clinical Significance“.
Drs. Isabelle Ragueneau-Majlessi and Jingjing Yu will give two talks at the upcoming 2023 Marbach DDI workshop, June 4-6, Marbach Castle, Germany.
Dr Isabelle Ragueneau-Majlessi will speak about the “Important Methodological Aspects of Smoking Interactions Studies – Review of three Decades of Literature”.
Dr Jingjing Yu will present an”Overview of 2022 NDA Reviews: Understanding the Risk of Metabolism- and Transporter-Based Drug-Drug Interactions with Novel Drugs Approved by the US FDA”.
In April, we added 111 citations in DIDB, including 40 in vitro (with 11 articles published in April 2023) and 71 in vivo articles (with 43 articles published in April 2023).
Four recently approved NDAs were also added: elacestrant (ORSERDU), omaveloxolone (SKYCLARYS), trofinetide (DAYBUE), zavegepant (ZAVZPRET).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
In March, we added 105 citations in DIDB, including 51 in vitro (with 16 articles published in March 2023) and 54 in vivo articles (with 38 articles published in March 2023).
Three recently approved NDAs and BLAs were also added: daprodustat (JESDUVROQ), pirtobrutinib (JAYPIRCA), velmanase alfa (LAMZEDE).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in April 2023, and is available in the DIDB Resource Center.
In this update, 38 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 6 compounds (16%) could lead to strong drug interactions mediated by CYP3A and CYP2D6.
In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.
As always, feel free to contact us if you have any questions or comments.
In February, we added 94 citations in DIDB, including 38 in vitro (with 16 articles published in February 2023) and 56 in vivo articles (with 38 articles published in February 2023).
Seven recently approved NDAs and BLAs were also added: anacaulase (NEXOBRID), bexagliflozin (BRENZVVY), lecanemab (LEQEMBI), lenacapavir (SUNLENCA), mosunetuzumab (LUNSUMIO), ublituximab (BRIUMVI), xenon Xe-129 hyperpolarized (XENOVIEW).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
We are pleased to announce the inclusion of FDA-issued Emergency Use Authorization (EUA) data in DIDB for PAXLOVID (nirmatrelvir and ritonavir) authorized for Covid-19 treatment.
Our DIDB editorial team has curated and entered in DIDB, all relevant pharmacokinetic (food effect, hepatic impairment, …) and drug interaction data (CYP3A, P-gp, …) obtained from CDER reviews.
You can review PAXLOVID comprehensive DDI drug monograph and search preclinical and clinical studies, case reports, modeling and simulation data of this combination drug and its components using various DIDB queries after login to DIDB and access the data here: https://lnkd.in/gr5QkpJK